Lewy Body Dementia and Parkinson's Disease: Spectrum Controversy and Clinical Implications

The relationship between Lewy body dementia (LBD) and Parkinson's disease (PD) centers on the Lewy body spectrum—neurodegenerative disorders defined by α-synuclein aggregates (Lewy bodies) in neurons.

Core Controversy

• Spectrum view: LBD and PD are phenotypic variants of one disease. Shared pathology (Lewy bodies in brainstem, cortex), overlapping symptoms (motor, cognitive, autonomic, psychiatric), and genetic risk (SNCA, GBA).
• Distinct entities view: PD = motor-predominant (substantia nigra Lewy bodies); LBD/DLB = dementia-predominant (cortical Lewy bodies early). Different diagnostic criteria, progression rates, treatment responses.

Diagnostic Frameworks

• PD dementia (PDD): Motor symptoms ≥1 year before dementia.
• Dementia with Lewy bodies (DLB): Dementia before or within 1 year of motor signs (1-year rule).
• LBD: Umbrella term encompassing both.

Implications

• Treatment: Cholinesterase inhibitors benefit DLB>PDD. Antipsychotics high-risk in both (neuroleptic sensitivity). Levodopa helps motor symptoms but may worsen psychosis.
• Prognosis: DLB declines faster than PDD.
• Research: Biomarkers (α-synuclein seed amplification, DaTscan, CSF) may resolve classification.

Clinical management prioritizes symptom control over diagnostic purity. Multidisciplinary care (neurology, psychiatry, palliative) optimizes quality of life.